RESEARCH AND EDUCATION DISCLAIMER
This article summarizes published scientific research for educational purposes only. Level Up Peptides products are intended exclusively for laboratory research by qualified researchers and are not for human or veterinary use. Discussion of published animal or human studies does not recommend those uses or establish the safety or effectiveness of any product sold on this website. This article does not provide medical advice, dosing guidance, or administration instructions.
SUMMARY
BPC-157 is an experimental peptide studied for its effects on cells and biological processes involved in tissue repair. Laboratory studies have examined tendon-cell movement, growth hormone receptor expression, and signaling associated with blood-vessel formation. These findings help explain scientific interest in the compound, but they do not establish that it repairs injuries in people. Published human research remains limited to small, uncontrolled studies. A 2026 systematic review rated the human evidence as very low certainty, highlighting the gap between experimental findings and reliable conclusions about human safety or effectiveness. [8]
WHAT IS BPC-157?
BPC-157 is a peptide made from 15 amino acids, the building blocks that also form proteins. The research literature describes it as a fragment associated with a gastric body protection compound. Researchers have investigated its effects in cultured cells, isolated tissues, and animal models, particularly in experiments involving tissue injury and repair. [1]
Understanding the experimental setting is essential. A result observed in cells grown in a laboratory is called an in vitro finding. Research involving isolated tissue is described as ex vivo, while experiments conducted in a living organism are in vivo. These approaches answer different questions and should not be treated as interchangeable evidence.
WHAT DO TENDON-CELL STUDIES SHOW?
A 2011 study examined BPC-157 using rat Achilles tendon tissue and tendon fibroblasts. Fibroblasts are cells involved in producing and maintaining the material surrounding cells in connective tissue.
The researchers reported increased cell movement, greater outgrowth from tendon tissue samples, and improved cell survival under an experimental oxidative-stress condition. BPC-157 did not directly increase cell proliferation in the assay used. This distinction matters: helping cells move or survive under particular laboratory conditions is different from demonstrating that a compound makes an injured tendon heal. [1]
The study also found increased activation of two signaling proteins, FAK and paxillin. These proteins participate in how cells attach to their surroundings and move. The findings suggest a possible explanation for the observed changes in cell behavior, rather than proof of a clinical treatment effect. [1]
HOW DOES BPC-157 RELATE TO GROWTH HORMONE SIGNALING?
A separate 2014 study investigated tendon fibroblasts isolated from rats. BPC-157 increased the expression of growth hormone receptors in these cells. When the researchers subsequently added growth hormone, they observed increased measures of cell proliferation and activation of a downstream signaling pathway called JAK2. [2]
In plain language, the experiment examined changes in how tendon cells responded to growth hormone. It did not demonstrate that BPC-157 causes the body to release more growth hormone, raises hormone levels in people, or produces a particular injury-recovery outcome. Those are different claims that this cell study did not test.
WHAT DOES BLOOD-VESSEL RESEARCH SHOW?
Blood-vessel formation, known as angiogenesis, is another area of BPC-157 research. A study published in the 2017 volume of the Journal of Molecular Medicine examined cultured human vascular endothelial cells, a chick membrane model, and rats with experimentally reduced blood flow to a limb.
The researchers reported changes associated with blood-vessel formation and increased expression of VEGFR2, a receptor involved in vascular signaling. In cultured cells, they also observed changes in the VEGFR2–Akt–eNOS signaling pathway. Although the cells were human-derived, experiments on those cells were laboratory studies, not clinical trials in people. [3]
These results identify mechanisms for further investigation. They do not establish that increasing this signaling is beneficial or safe in every biological setting, or that the same effects occur with commercially supplied research materials.
HOW MUCH EVIDENCE COMES FROM HUMAN STUDIES?
Most of the musculoskeletal evidence reviewed to date has been preclinical. A 2025 systematic review included 36 studies, of which 35 were preclinical and one was clinical. Its literature search ended in June 2024, so its findings should be understood within that timeframe. [4]
One frequently cited human report examined records of people who had received BPC-157 for knee pain. The researchers reached 16 people for telephone follow-up: 12 had received BPC-157 alone and four had received it with another peptide. Participants reported symptom improvements, but there was no randomized comparison group, and the study did not use standardized tools to assess function or quality of life. Those observations cannot establish structural repair or determine how much improvement was attributable to BPC-157. [5]
A separate pilot report described symptom changes in 12 women with interstitial cystitis, also called bladder pain syndrome. Its small size and lack of a control group limit what can be concluded from the reported improvements. [6]
A 2025 safety pilot involved only two adults. The authors reported no adverse effects during the short observation period. However, a study involving two people cannot establish long-term safety or reliably identify uncommon adverse effects. [7]
WHAT REMAINS UNCERTAIN?
An October 2026 systematic review assessed three human studies involving 30 participants. The reviewers judged the studies to have poor methodological quality and rated the overall certainty of evidence as very low. The main limitations included bias, small sample sizes, and uncertainty about how broadly the findings apply. [8]
For readers evaluating BPC-157 research, the central distinction is between a measurable biological effect and a demonstrated clinical benefit. Changes in cell movement, receptor expression, or experimental blood flow can generate useful research questions. Establishing human effectiveness and safety requires stronger evidence than those findings alone provide.
Published studies also concern the materials and conditions used by their investigators. They do not independently verify the identity, purity, stability, or biological activity of a different supplier’s product.
REFERENCES
1. Chang CH, Tsai WC, Lin MS, Hsu YH, Pang JHS. The promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell survival, and cell migration. Journal of Applied Physiology. 2011;110(3):774–780.
https://doi.org/10.1152/japplphysiol.00945.2010
2. Chang CH, Tsai WC, Hsu YH, Pang JHS. Pentadecapeptide BPC 157 enhances the growth hormone receptor expression in tendon fibroblasts. Molecules. 2014;19(11):19066–19077.
https://pubmed.ncbi.nlm.nih.gov/25415472/
3. Hsieh MJ, Liu HT, Wang CN, et al. Therapeutic potential of pro-angiogenic BPC157 is associated with VEGFR2 activation and up-regulation. Journal of Molecular Medicine. 2017;95(3):323–333.
https://doi.org/10.1007/s00109-016-1488-y
4. Vasireddi N, Hahamyan H, Salata MJ, et al. Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic Review. HSS Journal. 2025;21(4):485–495.
https://pubmed.ncbi.nlm.nih.gov/40756949/
5. Lee E, Padgett B. Intra-Articular Injection of BPC 157 for Multiple Types of Knee Pain. Alternative Therapies in Health and Medicine. 2021;27(4):8–13.
https://pubmed.ncbi.nlm.nih.gov/34324435/
6. Lee E, Walker C, Ayadi B. Effect of BPC-157 on Symptoms in Patients with Interstitial Cystitis: A Pilot Study. Alternative Therapies in Health and Medicine. 2024;30(10):12–17.
https://pubmed.ncbi.nlm.nih.gov/39325560/
7. Lee E, Burgess K. Safety of Intravenous Infusion of BPC157 in Humans: A Pilot Study. Alternative Therapies in Health and Medicine. 2025;31(5):20–24.
https://alternative-therapies.com/oa/pdf/11513.pdf
8. Poolton JT, Minett J, Kazmi A. Human evidence for BPC-157 in orthopaedic and regenerative medicine: a systematic review of efficacy and safety. Acta Orthopaedica Belgica. Published online October 8, 2026. DOI: 10.52628/92.3.15837.